Market Reports

A modern take on sterility assurance

Pharmaceutical manufacturers are increasingly looking for strategies to address containment risks. Christian Dunne of ChargePoint Technology sheds light on the benefit of split butterfly valve technology (SBV) in the aseptic processing of sterile active APIs and the final product

A look back at 2017 healthcare transactions

Last year, 2017, saw 2011 deals complete, with Q2 showing the strongest performance with 29.4%, followed by Q1 with 27.6%, Q3 with 24.1% and Q4 with 18.9%

Weathering the Brexit storm

The effective use of technology could facilitate regulatory compliance for pharmaceutical companies

Performance validation: HPAPI containment testing in a risk-based era

Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance

Gene transfer therapy approved for the treatment of ALL: part I

In August 2017, Novartis received FDA approval for its chimeric antigen receptor T (CAR-T) cell therapy, Kymriah, for the treatment of children and young adults with B-cell acute lymphoblastic leukaemia (ALL)

The race to be first: drug delivery systems for biosimilars

For biosimilar manufacturers, the market potential is significant, especially for those that are first to market

Improving cold chain performance and reliability

The need to mitigate risks within global pharmaceutical supply chain logistics is driving innovation within the temperature-controlled packaging sector

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CRDMOs are shaping the next generation of antibody-drug conjugates To explore how CRDMOs are leading innovation in ADC development, Dr Kevin Robinson spoke with Srivats Rajagopal, Senior Director, Cell and Protein Sciences, Biology Solutions at Aragen Life Sciences, about key technological advancements and evolving partnership models that are redefining what it means to outsource in this space
  2. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Start with the end in mind: the role of materials control in early CMC strategy for cell therapies Cell and gene therapy products are complex in their design, nature and mode of action. Because of this, the road to market can be a challenging one; littered with variables and failures, what might have been a valuable treatment often fails to reach much-in-need patients
  4. Freeze drying ADCs: points to consider for industrial applications As antibody-drug conjugates gain momentum in the pharmaceutical industry, manufacturers are increasingly looking to implement safe and effective process trains to produce them. Lyophilisation experts at GEA Pharma & Healthcare assess some of the most critical challenges and how to overcome them
  5. Rare diseases: understanding the patient journey In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all